Back

Trevena, Inc.

Trevena, Inc.
Company typePublic
Nasdaq: TRVN
Russell Microcap Index component
IndustryBiotechnology / Pharmaceutical
Headquarters
Chesterbrook, Pennsylvania
,
United States
Key people
Carrie L. Bourdow (president and CEO)
Websitetrevena.com

Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry [1] and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles.[2] Trevena was named one of the top 15 US startups of 2008 by Business Week.[3]

Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects.[4] Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease.[5]

  1. ^ "The Nobel Prize in Chemistry 2012". Nobelprize.org. 2012-10-10.
  2. ^ Violin, Jonathan D.; Lefkowitz, Robert J. (2007). "Β-Arrestin-biased ligands at seven-transmembrane receptors". Trends in Pharmacological Sciences. 28 (8): 416–22. doi:10.1016/j.tips.2007.06.006. PMID 17644195.
  3. ^ "Most Successful U.S. Startups 2008". Business Week. 2008-12-31. Archived from the original on December 22, 2008.
  4. ^ "Exploring GPCRs as Therapeutic Targets". Genetic Engineering News. 2013-04-15.
  5. ^ "Trevena Inc - Pipeline". Trevena Inc - Company Website. 2010-01-01.

Rich TVX News Network Site

Rich TVX News Network Info

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search